GlossaryTradFi
What Does Novo Nordisk (NVO) Do?
Novo Nordisk (NVO) is a Danish pharmaceutical company that holds global leadership in diabetes and obesity treatment. Follow NVO's price and technical analysis on COINOTAG.
Last updated Sources
Novo Nordisk is a Danish pharmaceutical company founded in 1923, operating in more than 185 countries with over a century of history. It trades on the NYSE as an American Depositary Receipt (ADR) under the ticker NVO. The company has grown to account for a significant portion of Denmark's GDP and has at times been Denmark's most valuable company.
What Is It and What Does It Do?
Novo Nordisk's business model is concentrated in two main therapeutic areas:
| Area | Key Products |
|---|---|
| Diabetes treatment | Ozempic (semaglutide), Victoza, Tresiba, NovoRapid (insulin) |
| Obesity treatment | Wegovy (high-dose semaglutide), Saxenda |
| Rare diseases | Norditropin (growth hormone), hemophilia treatments |
The company's defining catalyst is semaglutide, a GLP-1 receptor agonist. Ozempic is approved for diabetes and Wegovy — at a higher dose — is approved for obesity.
GLP-1 market share comparison — Ozempic/Wegovy (Novo Nordisk) vs. Mounjaro/Zepbound (Eli Lilly) in the 2022–2025 race
Why Does It Matter?
- Global obesity crisis: Approximately 1 billion people worldwide struggle with obesity. GLP-1 drugs not only reduce weight but clinical data shows they also reduce heart attack risk, sleep apnea, and diabetes.
- Market size: The GLP-1 market is projected to exceed $100 billion by 2030.
- Supply-side barrier: Rapidly scaling pharmaceutical production is challenging even for large drug companies, creating a temporary barrier to new entrants.
How is NVO traded?
The underlying (NVO) trades on its own market during that market's session hours.
NVO price and technical analysis →
Risks
- Competition: Eli Lilly's Mounjaro/Zepbound products are a formidable rival in the GLP-1 market
- Pricing pressure: Policy debates in the U.S. around drug price regulation could affect company margins
- Supply constraints: Production capacity lagging behind strong demand could limit near-term growth
- Clinical risk: Potential delays in second-generation obesity drug approvals (oral semaglutide, CagriSema)
- Currency risk: DKK/USD parity and global currency movements affect the ADR price
COINOTAG Perspective
Novo Nordisk offers a compelling growth story supported by structural demand in obesity and diabetes treatment. The market created by the GLP-1 category is driving a re-rating of both the company and the broader healthcare sector. While the competitive landscape and policy risks deserve attention, demographic trends will continue to support the sector over the long term.
Frequently Asked Questions
What is Novo Nordisk (NVO)?
Novo Nordisk is a Danish pharmaceutical company and global leader in diabetes and obesity treatment. It created the GLP-1 drug class with its Ozempic and Wegovy brands. It trades on the NYSE as an ADR under the NVO ticker.
What is the difference between Ozempic and Wegovy?
Both contain the molecule semaglutide. Ozempic is approved for diabetes treatment at a lower dose. Wegovy contains a higher dose of semaglutide and is specifically approved for obesity treatment and weight loss.
Where can I follow NVO's price and technical analysis?
You can follow NVO's price, chart and technical analysis on COINOTAG.
Who is Novo Nordisk's biggest competitor?
Eli Lilly, with Mounjaro (tirzepatide, for diabetes) and Zepbound (for obesity), is running a strong competition against Novo Nordisk in the GLP-1 market. Tirzepatide has demonstrated superior results versus semaglutide on certain clinical measures.